Program Overview
This CME/CNE program will highlight content presented at the Alzheimer’s Association International Conference (AAIC) 2018 held in Chicago, Illinois. The three expert faculty, led by Dr. Richard S. Isaacson, will provide an interactive account of recently released data regarding the treatment and management of patients with Alzheimer’s disease (AD). An overview of Alzheimer’s disease, including disease course, and signs and symptoms will be relayed. Emerged and emerging therapeutics will be discussed and clinical relevance debated. The faculty will emphasize an interprofessional approach to care in AD, highlighting strategies for engagement of the patient and caregiver. Upon completing this education, learners will better understand best practices for providing optimal, comprehensive care for patients with Alzheimer’s disease.
Target Audience
Neurologists, primary care physicians, internists, nurse practitioners, nurses, and other healthcare providers involved in the management of patients with Alzheimer’s disease
Learning Objectives
1. Analyze the most current clinical trial data for current and emerging therapeutics for the treatment of Alzheimer’s disease, as presented at AAIC 2018
2. Implement the interprofessional team into patient specific, evidence based therapeutic strategies to improve outcomes in patients with Alzheimer’s disease
Faculty
Richard S. Isaacson, MD (Course Chair)
Associate Professor of Neurology
Weill Cornell Medicine
Director, Alzheimer’s Prevention Clinic
New York Presbyterian Hospital
New York, New York
Howard Fillit, MD
Founding Executive Director and Chief Science Officer
The Alzheimer’s Drug Discovery Foundation
Clinical Professor of Geriatric Medicine, Palliative Care, Medicine, and Neuroscience
The Icahn School of Medicine at Mount Sinai
New York, New York
Barry W. Rovner, MD
Professor, Departments of Neurology, Psychiatry, and Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
| Faculty | Relationship Identified With: |
| Richard S. Isaacson, MD | Consultant/Advisor: Neurotrack Technologies, Inc. |
| Howard Fillit, MD | Consultant/Advisor: Axovant Sciences, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Lundbeck; Otsuka America Pharmaceutical, Inc.; Samus Therapeutics, Inc.; vTv Therapeutics |
| Barry W. Rovner, MD | Nothing to disclose. |
Planners, Managers, Reviewers
Timothy Hayes, MD, PhD; Emma Boring; Nicole Brestowski and Kim Cheramie, MSN, RN-BC hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AcademicCME is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour).
Financial Support
This activity is supported by independent educational grants from Biogen and Lilly USA, LLC.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME, Biogen and Lilly USA, LLC. do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
8. 60 minutes of participation = 1 CNE contact hour
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].
